In line with these findings, emerging drugs targeting m6A modification, such as a selective inhibitor of FTO, METTL3, and YTHDF2 have shown promising anti-cancer effects (Huang et al., 2015; Visvanathan et al., 2018; Dixit et al., 2021). This evidence concerns the gene METTL3 and cancer.